Is This the First of Many Legal Victories for Herbalife?

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

In the ongoing battle of Bill Ackman against Herbalife Ltd. (NYSE: HLF), it appears that Herbalife has struck a decisive blow. The lawsuit claimed that shareholders lost money because Herbalife portrayed itself as a legitimate company when really it was a “pyramid scheme,” or Ackman’s favorite term, “criminal enterprise.”

The decision was handed down in a district court in Los Angeles. The presiding judge determined that not enough evidence was presented by shareholders to prove that Herbalife had inflated its stock price by misrepresenting itself.

Ackman has been fighting Herbalife for more than two years now. Unlike most activists who might try to take over a company or influence its decisions, Ackman has taken a short position and wants to ride it all the way to zero.

Herbalife did come under observation in a probe by the Federal Trade Commission just a year ago, and the company may be exonerated in that probe, according to Bloomberg. However, this same probe came after Ackman accused Herbalife of misleading distributors, misrepresenting sales figures and selling a commodity product at inflated prices.

There was a rally in last Friday’s trading session that likely was due to the news that the government is looking into whether the market or stock was manipulated. Depending on that outcome, this could prove costly to Ackman in more ways than one.

Earlier this month, one analyst firm suggested that Herbalife fundamentals were feeling the weight of changes to the marketing plan, and as a result it lowered its price target.

Canaccord Genuity maintained its Buy rating for Herbalife but lowered its price target to $42 from $50, noting that the company is starting to feel like a value trap.

Shares of Herbalife jumped at the dismissal, up nearly 12% to $38.70 Wednesday morning. The stock has a consensus analyst price target of $57.80 and a 52-week trading range of $27.60 to $69.69.

ALSO READ: Companies Profiting the Most From War

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618